NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Forecast, Price & News

$9.85

-0.25 (-2.48%)

(As of 09/27/2023 ET)

Compare

Today's Range: $9.70
▼
$10.26
50-Day Range: $9.85
▼
$15.11
52-Week Range: $9.70
▼
$21.98

Volume: 88,547 shs
Average Volume: 200,407 shs
Market Capitalization: $402.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Mineralys Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 265.5% Upside
$36.00 Price Target
Short Interest: Bearish
9.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.61
Based on 2 Articles This Week
Insider Trading: Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.49) to ($2.85) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

569th out of 976 stocks

Pharmaceutical Preparations Industry

262nd out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
Mineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.00, Mineralys Therapeutics has a forecasted upside of 265.5% from its current price of $9.85.
Amount of Analyst Coverage
Mineralys Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.93% of the float of Mineralys Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Mineralys Therapeutics has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in Mineralys Therapeutics has recently increased by 18.79%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Mineralys Therapeutics does not currently pay a dividend.
Dividend Growth
Mineralys Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MLYS.

3.7

News and Social Media Coverage

News Sentiment
Mineralys Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mineralys Therapeutics insiders have sold 2,409.62% more of their company's stock than they have bought. Specifically, they have bought $80,185.00 in company stock and sold $2,012,336.00 in company stock.
Percentage Held by Institutions
61.66% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.85) per share.

See Top Rated MarketRank™ Stocks Here

About Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

MLYS Price History

30 days | 90 days | 365 days | Advanced Chart

MLYS Stock News Headlines

September 27, 2023 | americanbankingnews.com

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Recommendation of "Buy" from Brokerages

September 19, 2023 | finance.yahoo.com

Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

September 28, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 14, 2023 | finance.yahoo.com

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

September 11, 2023 | finance.yahoo.com

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

September 11, 2023 | finance.yahoo.com

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

September 10, 2023 | finance.yahoo.com

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

September 9, 2023 | finance.yahoo.com

CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS)

September 28, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

September 5, 2023 | finance.yahoo.com

Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?

September 5, 2023 | finance.yahoo.com

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

August 29, 2023 | finance.yahoo.com

Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023

August 22, 2023 | finance.yahoo.com

Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

August 8, 2023 | msn.com

Credit Suisse Maintains Mineralys Therapeutics (MLYS) Outperform Recommendation

August 8, 2023 | finance.yahoo.com

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 31, 2023 | finance.yahoo.com

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

July 28, 2023 | barrons.com

Mineralys Therapeutics Inc.

July 27, 2023 | seekingalpha.com

Mineralys Therapeutics: Expanded Phase 2 Trials For Chronic Kidney Disease

July 17, 2023 | finance.yahoo.com

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

May 31, 2023 | finance.yahoo.com

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

May 16, 2023 | msn.com

Credit Suisse Reiterates Mineralys Therapeutics (MLYS) Outperform Recommendation

May 16, 2023 | finanznachrichten.de

Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 16, 2023 | investing.com

Mineralys Therapeutics Inc (MLYS)

May 15, 2023 | finance.yahoo.com

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023 | msn.com

Markets Today: Stocks Slide Despite Optimism About the Debt Ceiling

May 10, 2023 | finance.yahoo.com

We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth

May 2, 2023 | finance.yahoo.com

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

See More Headlines

Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Company Calendar

Last Earnings: 8/07/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MLYS
CUSIP: N/A
CIK: 1933414
Web: www.mineralystx.com
Phone: 888-378-6240
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $36.00
High Stock Price Forecast: $45.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +265.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -27.88%
Return on Assets: -16.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 43.42
Quick Ratio: 43.42

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 40,860,000
Free Float: N/A
Market Cap: $402.47 million
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Jon Congleton (Age 60)
CEO & Director
Comp: $428.87k

Mr. Adam Scott Levy (Age 45)
CFO, Chief Bus. Officer & Sec.
Comp: $409.17k

Dr. David Rodman M.D. (Age 67)
Chief Medical Officer
Comp: $423.66k

Dr. Brian Taylor Slingsby M.D. (Age 46)
M.P.H., Ph.D., Founder & Exec. Chairman

Ms. Cindy Berejikian
Exec. VP of Operations

Dr. Robert McKean Ph.D.
Sr. VP of CMC

Ms. Danielle Bradbury
Sr. VP of Quality Assurance

Mr. Jeffrey N. Fellows
Sr. VP of Regulatory Affairs

Ms. Jessica Ibbitson
Sr. VP of Clinical Operations

Mr. Jose Breton CPA (Age 33)
VP of Fin. & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MLYS Stock - Frequently Asked Questions

Should I buy or sell Mineralys Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLYS shares.
View MLYS analyst ratings or view top-rated stocks.
What is Mineralys Therapeutics' stock price forecast for 2023?: 6 brokerages have issued twelve-month target prices for Mineralys Therapeutics' stock. Their MLYS share price forecasts range from $27.00 to $45.00. On average, they predict the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 265.5% from the stock's current price.
View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts.
How have MLYS shares performed in 2023?: Mineralys Therapeutics' stock was trading at $18.44 at the beginning of the year. Since then, MLYS stock has decreased by 46.6% and is now trading at $9.85.
View the best growth stocks for 2023 here.
When is Mineralys Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MLYS earnings forecast.
How were Mineralys Therapeutics' earnings last quarter?: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.52.
When did Mineralys Therapeutics IPO?: (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

What is Mineralys Therapeutics' stock symbol?: Mineralys Therapeutics trades on the NASDAQ under the ticker symbol "MLYS."
When did Mineralys Therapeutics' lock-up period expire?: Mineralys Therapeutics' lock-up period expired on Wednesday, August 9th. Mineralys Therapeutics had issued 12,000,000 shares in its IPO on February 10th. The total size of the offering was $192,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
Who are Mineralys Therapeutics' major shareholders?: Mineralys Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.16%), Sectoral Asset Management Inc. (1.50%), Great Point Partners LLC (1.34%), Driehaus Capital Management LLC (1.22%), Sphera Funds Management LTD. (0.99%) and Geode Capital Management LLC (0.70%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton and Ra Capital Management, LP.
View institutional ownership trends.
How do I buy shares of Mineralys Therapeutics?: Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mineralys Therapeutics' stock price today?: One share of MLYS stock can currently be purchased for approximately $9.85.
How much money does Mineralys Therapeutics make?: Mineralys Therapeutics (NASDAQ:MLYS) has a market capitalization of $402.47 million.
How can I contact Mineralys Therapeutics?: The official website for the company is www.mineralystx.com. The company can be reached via phone at 888-378-6240 or via email at investorrelations@mineralystx.com.

This page (NASDAQ:MLYS) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial